NO980556D0 - Procedure for reducing the amount of exogenous insulin administered to a patient with non-insulin-dependent diabetes mellitus - Google Patents

Procedure for reducing the amount of exogenous insulin administered to a patient with non-insulin-dependent diabetes mellitus

Info

Publication number
NO980556D0
NO980556D0 NO980556A NO980556A NO980556D0 NO 980556 D0 NO980556 D0 NO 980556D0 NO 980556 A NO980556 A NO 980556A NO 980556 A NO980556 A NO 980556A NO 980556 D0 NO980556 D0 NO 980556D0
Authority
NO
Norway
Prior art keywords
insulin
patient
procedure
reducing
amount
Prior art date
Application number
NO980556A
Other languages
Norwegian (no)
Other versions
NO980556L (en
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO980556L publication Critical patent/NO980556L/en
Publication of NO980556D0 publication Critical patent/NO980556D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO980556A 1995-08-10 1998-02-09 Procedure for reducing the amount of exogenous insulin administered to a patient with non-insulin-dependent diabetes mellitus NO980556D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US209895P 1995-08-10 1995-08-10
PCT/US1996/012430 WO1997005875A2 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Publications (2)

Publication Number Publication Date
NO980556L NO980556L (en) 1998-02-09
NO980556D0 true NO980556D0 (en) 1998-02-09

Family

ID=21699238

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980556A NO980556D0 (en) 1995-08-10 1998-02-09 Procedure for reducing the amount of exogenous insulin administered to a patient with non-insulin-dependent diabetes mellitus

Country Status (15)

Country Link
EP (1) EP0851757A2 (en)
JP (1) JPH11510508A (en)
KR (1) KR19990036290A (en)
CN (1) CN1192683A (en)
AU (1) AU724989B2 (en)
BG (1) BG102235A (en)
CA (1) CA2221241A1 (en)
CZ (1) CZ32998A3 (en)
EA (1) EA199800177A1 (en)
HU (1) HUP9802543A2 (en)
IL (1) IL122191A0 (en)
NO (1) NO980556D0 (en)
NZ (1) NZ313874A (en)
SK (1) SK16498A3 (en)
WO (1) WO1997005875A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
FR2838968A1 (en) * 2002-04-30 2003-10-31 Lipha ASSOCIATION OF INSULIN AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR TREATING DIABETES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (en) * 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
CA2221241A1 (en) 1997-02-20
KR19990036290A (en) 1999-05-25
IL122191A0 (en) 1998-04-05
NO980556L (en) 1998-02-09
AU6641196A (en) 1997-03-05
JPH11510508A (en) 1999-09-14
EA199800177A1 (en) 1998-10-29
AU724989B2 (en) 2000-10-05
CN1192683A (en) 1998-09-09
EP0851757A2 (en) 1998-07-08
BG102235A (en) 1998-09-30
NZ313874A (en) 2000-09-29
WO1997005875A3 (en) 1997-03-27
WO1997005875A2 (en) 1997-02-20
HUP9802543A2 (en) 1999-07-28
SK16498A3 (en) 1999-03-12
CZ32998A3 (en) 1998-10-14

Similar Documents

Publication Publication Date Title
PH23014A (en) Novel insulin derivatives,their use and pharmaceutical agents for the treatment of diabetes mellitus
CA2024502A1 (en) Dosage form for administering oral hypoglycemic glipizide
DE69111832D1 (en) Naproxen formulation for controlled absorption for once daily use.
AU4282793A (en) A microneedle for injection of ocular blood vessels
AU2847389A (en) Single-use syringe
AU1924795A (en) Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration
FR2623806B1 (en) ESTERS OF 3,6-DIHYDRO-1,5 (2H) -PYRIMIDINECARBOXYLIC ACIDS WITH THERAPEUTIC ACTION
NO980556D0 (en) Procedure for reducing the amount of exogenous insulin administered to a patient with non-insulin-dependent diabetes mellitus
CA2113856A1 (en) Antidiabetic Agent
AU5352190A (en) Single-use syringe for injections
GB8911818D0 (en) Single-use hypodermic syringe adaptor therefor
AU4967390A (en) Single-use syringe for injections
ES2181923T3 (en) 4-HYDROXICUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABET IS MELLITUS NOT INSULIN DEPENDENT.
DK0785787T3 (en) Use of 1,5-benzodiazepine derivatives to control gastric emptying in patients with non-insulin-dependent diabetes mellitus
ATE124627T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DICLOFENAC SODIUM FOR TOPICAL USE.
EP0355591A3 (en) Implantable medicament-dosing device for the injection of a liquid medicament into a living organ
AU3751193A (en) Syringe for medical use with non-reusable automatically disappearing needle
MX9709958A (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus.
USD323030S (en) Medical syringe for administering subcutaneous injections
AU4553593A (en) Treatment of diabetes using phosphorylated insulin
NO20001895D0 (en) Use of glycosaminoglycans for the preparation of pharmaceutical preparations for the treatment of diabetes-associated eye diseases
IL94241A0 (en) Diagnosis and treatment of insulin dependent diabetes mellitus
GB2234175B (en) Mono-use syringe for hypodermic injections
AU5031690A (en) Single-use syringe for injections
IL85895A0 (en) Combined insulin forms for controlling diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application